180 Life Sciences Corp Stock Price, News & Analysis

180 Life Sciences Corp. (NASDAQ: ATNF) announced positive final results from its Phase 2b study of anti-TNF treatment for Dupuytren's disease, published in The Lancet Rheumatology. The study achieved its primary endpoint of reduced nodule hardness at 12 months and demonstrated ongoing improvement at 18 months, suggesting durable benefits from treatment. The trial showed a decrease in nodule size and high patient compliance, with no serious adverse events reported. This study supports anti-TNF therapy as a promising early treatment option for Dupuytren's disease, which currently lacks approved therapies.

180 Life Sciences Corp. (NASDAQ: ATNF) has formed a scientific advisory board (SAB) to enhance its clinical development capabilities. The board includes notable experts such as Dr. Raphael Mechoulam and Dr. Kevin Tracey, who will guide the company's focus on inflammatory diseases and pain management. Following recent positive Phase 2b results in Dupuytren’s Contracture, 180 Life Sciences is set to discuss regulatory pathways with the FDA and MHRA. This strategic move aims to strengthen its pipeline and expedite commercialization efforts.

180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology firm, addressed shareholders in a letter from CEO Dr. James Woody, acknowledging recent market declines impacting stock prices. The letter highlighted continued confidence in the company's fundamentals following positive Phase 2b trial results for Dupuytren’s Contracture, with anticipated publication in a peer-reviewed journal. The company, targeting a significant market opportunity estimated at $800M, is pursuing regulatory approvals and exploring strategic partnerships. Financial discipline is emphasized to navigate macroeconomic headwinds.

180 Life Sciences Corp. (NASDAQ: ATNF) announced its participation in the Biotech Showcase 2022 Virtual Conference from January 10-12, 2022. Dr. James Woody, the Company's CEO, will present an overview of its business and is available for virtual meetings. The conference focuses on innovations in the life sciences industry, covering recent opportunities and challenges. 180 Life Sciences is dedicated to developing novel drugs for inflammatory diseases, fibrosis, and pain, leveraging expertise from notable institutions like Oxford and Stanford.

180 Life Sciences (NASDAQ: ATNF) has announced a global licensing agreement with The University of Oxford for the development of HMGB1, a regenerative molecule aimed at promoting liver repair. The agreement involves a small upfront fee with additional payments contingent on clinical milestones. This initiative targets liver disorders such as NASH, a condition with no approved therapies. The collaboration aims to advance GMP production and safety testing in preparation for an Investigational New Drug application.

180 Life Sciences Corp. (NASDAQ: ATNF) announced positive top-line results from its Phase 2b clinical trial for Dupuytren’s disease, demonstrating significant reductions in nodule hardness and size. The trial met both primary and secondary endpoints, showing high patient compliance without serious adverse events. Although detailed data cannot be released due to publication policies, the Company anticipates commercialization discussions with regulatory bodies in 2022. 180 Life Sciences aims to lead in fibrosis therapies, with no current competitors for early-stage Dupuytren’s disease treatments.

180 Life Sciences Corp. (NASDAQ: ATNF) announced a keynote by Professor Jagdeep Nanchahal at the 2021 International Dupuytren Symposium on December 1, 2021. The presentation focused on re-purposing anti-TNF for Dupuytren’s disease and disclosed promising phase 2b clinical trial results. The trial met primary and secondary endpoints, showing significant improvement in nodule hardness and size, with no severe adverse events reported. The full results are pending publication in a peer-reviewed journal, indicating a potential new therapeutic approach for Dupuytren’s disease.

180 Life Sciences Corp. (ATNF) announced the extension of its patent portfolio with new patents granted in the US and Canada for methods treating chronic pain using specific phenyl substituted cyclohexenyl compounds related to cannabidiol (CBD). These patents complement existing protections in Europe, China, and Israel. The company is focusing on synthetic cannabidiol analogues aimed at improving pain management for patients with rheumatoid arthritis. CEO Dr. James Woody noted the potential of these compounds to address unrelieved pain in patients not responding to current therapies.

180 Life Sciences Corp. (NASDAQ: ATNF) announced that Professor Jagdeep Nanchahal will present a keynote on ‘Re-purposing anti-TNF for Dupuytren’s Disease’ at the 2021 International Dupuytren Symposium on December 1, 2021. He will discuss the molecular mechanisms of Dupuytren’s disease and share data from phase 2a and 2b clinical trials. Additionally, the company anticipates starting a frozen shoulder clinical trial in early 2022. 180 Life Sciences is focusing on innovative drug development for unmet needs in inflammatory diseases and fibrosis.